ArticleJournal of cellular and molecular medicine2026
Metabolic Dysregulation of FC3 Fibrochondrocytes via MDH2 Promotes Intervertebral Disc Degeneration.
Article in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Intervertebral disc degeneration (IDD) is a primary cause of chronic low back pain, yet the specific cell subpopulations and metabolic mechanisms driving its progression remain incompletely understood. We performed an integrative analysis of single-cell RNA sequencing (scRNA-seq) and transcriptomic sequencing using public datasets (GSE230809, GSE186542) to characterise cellular heterogeneity in IDD. To elucidate the underlying pathological mechanisms, we employed senescence scoring, transcriptional entropy assessment, pseudotime trajectory inference, and hierarchical weighted gene co-expression network analysis (hdWGCNA). Metabolic pathway activity was evaluated with scMetabolism, and potential therapeutics were screened using the POINT platform. We identified a key fibrochondrocyte subpopulation, FC3, which exhibits high transcriptional entropy and plays a central role in IDD. The FC3 cluster was further resolved into three functional states: fibrotic, proliferative, and metabolic. Pseudotime trajectory inference indicated that FC3 (proliferative) cells potentially represent a progenitor-like state, partitioning toward fibrotic and metabolic lineages. Notably, the FC3 (metabolic) state displayed the lowest senescence score and the highest activity in the tricarboxylic acid (TCA) cycle. Through hdWGCNA and cross-dataset validation, malate dehydrogenase 2 (MDH2) was established as a central hub gene linking TCA cycle activation to the FC3 (metabolic) phenotype. Functional enrichment confirmed MDH2's role in oxidative phosphorylation, fatty acid metabolism, and cellular senescence. Drug screening identified several candidate compounds, including Platycodin D, Irbesartan, and Ergothioneine, whose corresponding targets exhibited specifically enhanced activity within the FC3 (metabolic) subpopulation of degenerated tissues. Our study reveals that metabolic dysregulation in the FC3 fibrochondrocyte subpopulation, driven by aberrant MDH2-mediated TCA cycle activation, is a critical mechanism promoting IDD. These findings highlight the therapeutic targeting value of the FC3 metabolic state and provide specific candidate compounds for the subsequent development of interventions against IDD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.